MIT Technology Review :press: on Nostr: Chasing AI’s value in life sciences Inspired by an unprecedented opportunity, the ...
Chasing AI’s value in life sciences
Inspired by an unprecedented opportunity, the life sciences sector has gone all in on AI. For example, in 2023, Pfizer introduced an internal generative AI platform expected to deliver $750 million to $1 billion in value. And Moderna partnered with OpenAI in April 2024, scaling its AI efforts to deploy ChatGPT Enterprise, embedding the tool’s… #press
https://www.technologyreview.com/2024/10/31/1106332/chasing-ais-value-in-life-sciences/?utm_source=press.coop
Inspired by an unprecedented opportunity, the life sciences sector has gone all in on AI. For example, in 2023, Pfizer introduced an internal generative AI platform expected to deliver $750 million to $1 billion in value. And Moderna partnered with OpenAI in April 2024, scaling its AI efforts to deploy ChatGPT Enterprise, embedding the tool’s… #press
https://www.technologyreview.com/2024/10/31/1106332/chasing-ais-value-in-life-sciences/?utm_source=press.coop